NASDAQ · CTOR
Healthcare · Drug Manufacturers - General
$0.78
Down-$0.01 (-1.86%)
Updated Aug 31, 2026, 12:06 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CTOR closed at $0.78 after 20 trading sessions, up 24.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $0.80 | $0.80 | $0.7538 | $0.7756 | 21.7K |
| Aug 27, 2026 | $0.8275 | $0.83 | $0.7903 | $0.7903 | 8.57K |
| Aug 26, 2026 | $0.7908 | $0.82 | $0.7516 | $0.7871 | 17.08K |
| Aug 25, 2026 | $0.705 | $0.818 | $0.705 | $0.8101 | 134.13K |
| Aug 24, 2026 | $0.759 | $0.76 | $0.7222 | $0.75 | 16.69K |
| Aug 21, 2026 | $0.721 | $0.7549 | $0.721 | $0.7438 | 13.46K |
| Aug 20, 2026 | $0.7524 | $0.7734 | $0.71 | $0.7591 | 52.09K |
| Aug 19, 2026 | $0.73 | $0.78 | $0.6801 | $0.7525 | 58.03K |
| Aug 18, 2026 | $0.7178 | $0.7178 | $0.6594 | $0.703 | 86.69K |
| Aug 17, 2026 | $0.735 | $0.7816 | $0.7003 | $0.74 | 274.96K |
| Aug 14, 2026 | $0.8268 | $0.935 | $0.8009 | $0.9098 | 297.25K |
| Aug 13, 2026 | $0.82 | $0.85 | $0.7851 | $0.8268 | 81.09K |
| Aug 12, 2026 | $0.7252 | $0.8142 | $0.7072 | $0.8115 | 59.33K |
| Aug 11, 2026 | $0.743 | $0.743 | $0.7064 | $0.73 | 23.8K |
| Aug 10, 2026 | $0.76 | $0.76 | $0.7163 | $0.7375 | 75.08K |
| Aug 7, 2026 | $0.789 | $0.789 | $0.7332 | $0.753 | 45.24K |
| Aug 6, 2026 | $0.795 | $0.795 | $0.71 | $0.76 | 179.38K |
| Aug 5, 2026 | $0.63 | $0.89 | $0.63 | $0.785 | 1.04M |
| Aug 4, 2026 | $0.6793 | $0.68 | $0.64 | $0.66 | 74.13K |
| Aug 3, 2026 | $0.64 | $0.68 | $0.5535 | $0.6254 | 95.07K |
The latest Smart Investors Daily articles mentioning CTOR.
CTOR research
Company profile and research snapshot.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2025 | Maxim Group | Buy | — |
| May 23, 2025 | Maxim Group | Hold | — |
| Nov 27, 2024 | Maxim Group | Buy | — |
| Aug 13, 2024 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Yahoo · Aug 12, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.
Yahoo · Aug 5, 2026
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.
Benzinga · Feb 13, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTOR.
